Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Evotec receives €6 million in milestones

This article was originally published in Scrip

Executive Summary

Evotec has received €6 million for achieving two research milestones through its drug discovery collaboration with Boehringer Ingelheim. One milestone was for the start of lead optimisation for a specific target, while the other was for a separate programme in which Boehringer Ingelheim selected a compound for preclinical development. Boehringer Ingelheim will be responsible for the preclinical development of the identified compound, while Evotec will be entitled to additional royalties based on the compound's progress through clinical development. The two firms have been collaborating since 2004 on identifying and developing preclinical candidates for the treatment of various diseases, including CNS-related disorders, and the arrangement has been expanded and extended since its initiation. Boehringer Ingelheim has full ownership and global responsibility for developing, manufacturing and commercialising identified compounds, while Evotec receives ongoing research payments and preclinical milestones.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts